---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-23-000014"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T10:38:51.182450+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15

## Summary
- Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.
- HIV sales $4.2B (+13%); Biktarvy sales $2.7B (+24%); Oncology sales $670M (+59%).
- Non-GAAP diluted EPS $1.37 vs $2.12 YoY; GAAP EPS $0.80 vs $0.02.
- GAAP EPS guidance lowered to $4.75-$5.15 from $5.30-$5.70; non-GAAP unchanged $6.60-$7.00.
- Cash & equivalents $7.2B; paid $969M dividends, repurchased $400M stock in Q1.

## SEC filing metadata
- accession: 0000882095-23-000014
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/gild-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-23-000014
- JSON: https://secwatch.observer/filing/0000882095-23-000014.json
- Plain text: https://secwatch.observer/filing/0000882095-23-000014.txt

## Key facts
- Earnings Releases
  GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.
  - Period: first quarter of 2023
  - EPS: Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022
  - Result: reported results
  source text: Total first quarter 2023 revenue decreased 4% to $6.4 billion compared to the same period in 2022, due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and Oncology.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm
- Earnings Releases
  GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.
  - Period: first quarter of 2023
  - EPS: Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022
  - Result: reported results
  source text: Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.